Northwestern Mutual Wealth Management Co. Sells 448,705 Shares of Boston Scientific Corporation $BSX

Northwestern Mutual Wealth Management Co. trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 66.8% in the 4th quarter, Holdings Channel reports. The firm owned 223,374 shares of the medical equipment provider’s stock after selling 448,705 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Boston Scientific were worth $21,299,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of BSX. Murphy & Mullick Capital Management Corp boosted its holdings in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. United Community Bank lifted its holdings in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the last quarter. Colonial Trust Co SC lifted its holdings in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. Finally, Bangor Savings Bank lifted its holdings in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported positive pivotal FRACTURE trial results for its investigational SEISMIQ 4CE coronary intravascular lithotripsy catheter, with the device meeting both primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The data should help support an FDA filing and strengthens the company’s growth outlook in interventional cardiology. Article Title
• Positive Sentiment: The company also announced a $2 billion accelerated share repurchase program, which signals confidence from management and should help reduce share count, providing a near-term earnings-per-share tailwind. Article Title
• Positive Sentiment: Boston Scientific said it invested $1.5 billion in MiRus for about a 34% stake and obtained an option to buy the startup’s TAVR business, giving BSX a potential path into a large structural heart market and another long-term growth catalyst. Article Title
• Neutral Sentiment: Analyst commentary remained mostly constructive, with several firms reiterating buy/outperform ratings even as some price targets were trimmed, suggesting Wall Street still sees upside despite a lower valuation framework. Article Title
• Neutral Sentiment: Healthcare sector strength also provided a mild tailwind, with the broader group rising late in the session. Article Title
• Negative Sentiment: Offsetting the positives, Robert W. Baird and Bank of America both lowered price targets on BSX, which may temper enthusiasm even though both firms kept constructive ratings. Article Title

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a report on Friday, February 6th. Stifel Nicolaus dropped their price objective on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Canaccord Genuity Group dropped their price objective on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, Barclays dropped their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.71.

Boston Scientific Price Performance

BSX stock opened at $56.78 on Wednesday. The firm’s 50-day moving average price is $62.77 and its two-hundred day moving average price is $81.02. Boston Scientific Corporation has a 12-month low of $52.52 and a 12-month high of $109.50. The stock has a market capitalization of $84.39 billion, a price-to-earnings ratio of 23.76, a PEG ratio of 1.02 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the company earned $0.75 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific declared that its board has initiated a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.